Analysts Set LifeMD, Inc. (NASDAQ:LFMD) Price Target at $11.14

Shares of LifeMD, Inc. (NASDAQ:LFMD) have received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $11.14.

A number of equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of LifeMD in a research report on Monday, November 11th. KeyCorp decreased their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Lake Street Capital began coverage on shares of LifeMD in a report on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price target for the company. Finally, Mizuho began coverage on shares of LifeMD in a report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target for the company.

LifeMD Stock Performance

Shares of LFMD opened at $4.67 on Friday. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The company has a 50 day moving average price of $5.66 and a 200-day moving average price of $5.38. The stock has a market capitalization of $202.27 million, a PE ratio of -7.30 and a beta of 1.50.

Insider Transactions at LifeMD

In other news, CEO Justin Schreiber sold 50,000 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $7.55, for a total value of $377,500.00. Following the sale, the chief executive officer now owns 2,653,715 shares in the company, valued at $20,035,548.25. This represents a 1.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.97% of the company’s stock.

Institutional Trading of LifeMD

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ProShare Advisors LLC acquired a new stake in LifeMD during the fourth quarter valued at $51,000. Oxford Asset Management LLP acquired a new stake in LifeMD during the fourth quarter valued at $52,000. Balyasny Asset Management L.P. acquired a new stake in LifeMD during the fourth quarter valued at $52,000. Intech Investment Management LLC acquired a new stake in LifeMD during the third quarter valued at $54,000. Finally, AXQ Capital LP acquired a new stake in LifeMD during the fourth quarter valued at $57,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.